Caris Life Sciences vs Pennant Group
Pennant Group is the larger business, with $948m of revenue in fiscal 2025 against $812m for Caris Life Sciences (1.2 times as much). Caris Life Sciences grew faster (97.0% against 36.3%). Pennant Group kept more of each dollar of sales as profit: a net margin of 3.1% against -8.4%. Pennant Group carries less debt relative to equity (46.8% against 65.6%).
| Latest fiscal year | Caris Life SciencesCAI, 2025 | Pennant GroupPNTG, 2025 |
|---|---|---|
| Revenue | $812m | $948m |
| Revenue growth | 97.0% | 36.3% |
| Net income | −$68.1m | $29.6m |
| Operating margin | 5.6% | 5.5% |
| Net margin | -8.4% | 3.1% |
| Return on equity | — | 8.6% |
| Free cash flow | $66.9m | $36.3m |
| Cash | $796m | $17.0m |
| Total debt | $379m | $175m |
| Debt to equity | 65.6% | 46.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $113,000 | — |
| Employees | 1,846 | 9,700 |
| Market value | $9.33bn | $1.43bn |
| Price vs our value range | — | Within our value range |
| Moat score | — | 21 (Weak) |
| Insider trades, 12 months | 4 buys, 7 sales | 0 buys, 9 sales |